Laura Rosiñol

Research interests

Publications

• Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2023 · https://doi.org/10.1056/nejmoa2312054

• Extramedullary disease in multiple myeloma: a systematic literature review

  Blood Cancer Journal · 2022 · 10.1038/s41408-022-00643-3

• Teclistamab in Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478

• Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

  The Lancet · 2021 · 10.1016/s0140-6736(21)01338-6

• Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma

  Journal of Clinical Oncology · 2019 · https://doi.org/10.1200/jco.19.01231

• Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel

  Journal of Hematology & Oncology · 2018 · https://doi.org/10.1186/s13045-017-0549-1

• Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.69.2517

• Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

  Leukemia · 2017 · https://doi.org/10.1038/leu.2017.138

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · https://doi.org/10.1016/s1470-2045(15)00464-7

• International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

  The Lancet Oncology · 2014 · https://doi.org/10.1016/s1470-2045(14)70442-5

• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2014 · https://doi.org/10.1056/nejmoa1411321

• Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma

  Blood · 2014 · https://doi.org/10.1182/blood-2014-01-550020

• Lenalidomide plus Dexamethasone for High-Risk Smoldering Multiple Myeloma

  New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmoa1300439

• Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials

  Journal of Clinical Oncology · 2013 · 10.1200/jco.2012.48.4626

• Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70398-x

• Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

  Blood · 2012 · 10.1182/blood-2012-02-408922

• Soft-Tissue Plasmacytomas in Multiple Myeloma: Incidence, Mechanisms of Extramedullary Spread, and Treatment Approach

  Journal of Clinical Oncology · 2011 · 10.1200/jco.2011.34.9290

• High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

  Blood · 2011 · https://doi.org/10.1182/blood-2011-07-370460

• Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

  Blood · 2011 · https://doi.org/10.1182/blood-2011-06-358812

• Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma

  Journal of Clinical Oncology · 2008 · 10.1200/jco.2007.14.1853

• Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple Myeloma: Sequential Improvement of Response and Achievement of Complete Response Are Associated With Longer Survival

  Journal of Clinical Oncology · 2008 · https://doi.org/10.1200/jco.2008.17.9721

• Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis

  Blood · 2008 · https://doi.org/10.1182/blood-2008-04-147884

• Pathogenesis and treatment of renal failure in multiple myeloma

  Leukemia · 2008 · 10.1038/leu.2008.131

• A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma

  Blood · 2008 · 10.1182/blood-2008-02-141598

Current projects

No projects listed.